Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Butyrophilin subfamily 1 member A1 (BTN1A1) is a membrane-associated glycoprotein belonging to the immunoglobulin superfamily. It plays a crucial role in milk fat droplet secretion and acts as an immune checkpoint molecule, suppressing T-cell activation. It is highly expressed in several solid tumor types, where it contributes to immune evasion. It has also been implicated in the pathogenesis of multiple sclerosis.
BTN1A1 blockade enhances antitumor immunity by increasing immune cell infiltration into tumors. It inhibits proliferation of CD4+ and CD8+ T-cells activated by anti-CD3 antibodies; reduces IL2 and IFNG secretion from these cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Butyrophilin subfamily 1 member A1 (BTN1A1).